Woodinville, WA, United States of America

Anna S Gall

USPTO Granted Patents = 33 (Patent Applications = 8)

CIPO Patents = 5

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 7.2

ph-index = 6

Forward Citations = 161(Granted Patents)

Company Filing History:

University of Washington

Genevant Sciences Gmbh

patents

5. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12029708 - Alkoxy compounds for disease treatment (2024-07-09),

2. 11707483 - Micellic assemblies (2023-07-25),

3. 11446261 - Alkoxy compounds for disease treatment (2022-09-20),

4. 10639286 - Alkoxy compounds for disease treatment (2020-05-05),

5. 10420790 - Micellic assemblies (2019-09-24),

6. 10201545 - Styrenyl derivative compounds for treating ophthalmic diseases and disorders (2019-02-12),

7. 10188615 - Alkoxy compounds for disease treatment (2019-01-29),

8. 9862792 - Diblock copolymers and polynucleotide complexes thereof for delivery into cells (2018-01-09),

9. 9737496 - Alkoxy compounds for disease treatment (2017-08-22),

10. 9662403 - Micellic assemblies (2017-05-30),

11. 9493500 - Fluorinated pyrimidine analogs and methods of use thereof (2016-11-15),

12. 9476063 - Diblock copolymers and polynucleotide complexes thereof for delivery into cells (2016-10-25),

13. 9464300 - Multiblock copolymers (2016-10-11),

14. 9464033 - Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders (2016-10-11),

15. 9458088 - Alkoxy compounds for disease treatment (2016-10-04),

Title: Innovations and Contributions of Anna S Gall in Neuroscience

Introduction

Anna S Gall is a prominent inventor based in Woodinville, WA, recognized for her significant contributions to the field of neurodegenerative disease treatment. With an impressive portfolio of 33 patents, her work focuses on innovative compounds and methods that could revolutionize how ophthalmic diseases are treated.

Latest Patents

Two of her latest patents exemplify her groundbreaking approach to medical science. The first patent involves alkoxy compounds specifically designed for the treatment of neurodegenerative diseases and disorders. This invention is particularly notable for its applications in treating ophthalmic conditions, including age-related macular degeneration (AMD) and Stargardt's Disease. The compositions and methods outlined in this patent offer exciting potential for improving outcomes for patients suffering from these debilitating diseases.

The second patent addresses micellic assemblies composed of various copolymers, which are pH-sensitive particles. This innovation is significant as it opens up new possibilities in the development of targeted therapies that could enhance drug delivery methods in biomedicine.

Career Highlights

Throughout her career, Anna has made substantial contributions while working with notable organizations, including Acucela Inc. and the University of Washington. Her experience in these institutions has undoubtedly enriched her understanding and capabilities in the field of drug development and patenting.

Collaborations

Anna has collaborated with esteemed professionals like Mark W Orme and Ian L Scott, illustrating her ability to work effectively within interdisciplinary teams. These collaborations have likely contributed to her innovative discoveries and successful patent applications.

Conclusion

Anna S Gall's work not only showcases her passion for innovations in medical treatments but also highlights her role as a key figure in the fight against neurodegenerative diseases. Through her numerous patents, she continues to pave the way for new therapeutic strategies that hold promise for improving patient care in ophthalmic disorders.

This text is generated by artificial intelligence and may not be accurate.